INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019 TR1 – Notification of Major Interest – Lanstead Capital Investors TR1 – Notification of Major Shareholding 2019 Annual General Meeting – All resolutions passed Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Subscription to raise £2.66 million Notice of AGM and posting of Report & Accounts FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2018 Corporate Update Update on Nucant cancer programme IMM March 2019 Corporate Update Technology review published in Nature Communications Appointment of NOMAD Update on Corporate Activities Nominated Adviser Status Interim results announcement for the six months ended 30 June 2018 Standford Capital Partners and Si Capital are appointed as joint broker IMM September 2018 Corporate Update 2018 Annual General Meeting – All Resolutions Passed ImmuPharma announces positive pre-clinical data on its CIDP programme Annual Report and Accounts Posted to Shareholders Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort1 Holding in company Immupharma PLC confident on Lupuzor’s™ future Holding in company Holding in company Top line results of Lupuzor™ Pivotal Phase III Trial Appointment of Joint Broker Lupuzor™ ‘database lock’ confirmed for 6 April 2018 London Investor Evening – Monday 26 February 2018 @ 6pm Holding in Company Notification of Major Interest – Lanstead Increases Holding to over 5% Successful Placing to Raise £10 Million Completion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study Update on Lupuzor™ Pivotal Phase III Study ImmuPharma PLC (“ImmuPharma” or the “Company”) Holding(s) in Company Successful Completion of Lanstead Sharing Agreement Interim Results Announcement for the six months ended 30 June 2017 ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions Update on Lupuzor™ Pivotal Phase III Study 2017 Annual General Meeting – All Resolutions Passed Annual General Meeting and Investor Presentation Notice of Annual General Meeting on 30 June 2017 at 10.30am Final Results Announcement for the twelve months ended 31 December 2016 Notification of full year results – 1st June 2017 Update on Lupuzor™ Pivotal Phase III Study Notification of Major Interest by Legal & General Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild Accelerated Bookbuild for the Issue of Equity Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment Change of Adviser Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed Update on Cancer Compound IPP-204106 ‘Nucant’ Notification of Major Interest by Legal & General TR1 Notification of Major Interest Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity Close of Accelerated Bookbuild INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016 Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting ImmuPharma Invited to Open an Additional Site in Mauritius ImmuPharma Invited to Open an Additional Site in Mauritius Northland Capital Appointed as Joint Broker Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Notification of Major Interest by Alto Invest to 4.15% Notification of Major Interest by Alto Invest PRELIMINARY RESULTS
for the year ended 31 December 2015 Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016 Notification of Preliminary Results. Date: 4 May 2016 First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription Result of GM First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study Placing and Subscription Raises £8.3 million Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016 Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients Lupuzor™ Phase III Pivotal Trial Update Board Change Tim McCarthy Appointed as Non-executive Chairman Interim Results Announcement for the six months ended 30 June 2015 Richard Warr ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™ Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™ ANNUAL GENERAL MEETING: 2015 Notice of Annual General Meeting: 29 May 2015 Preliminary Results Announcement for the year ended 31 December 2014 Dr Stéphane Méry Appointed as Non-Executive Director Cancer Update: IPP-204106 Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014 Lupuzor™ Gears Up To Start Pivotal Phase III trials ANNUAL GENERAL MEETING: 2014 ImmuPharma to access pioneering research in the Bordeaux region of France New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014 Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan ImmuPharma Sponsors the 2014 European Lupus Conference UPDATE: Cancer Programme IPP-204106 FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Appointment of Scientific Advisory Board ImmuPharma secures £50M financing facility for Lupuzor Phase III Immupharma gets Lupuzor research boost ImmuPharma Commences Trading on the Stuttgart Stock Exchange CNRS Confirms Lupuzor’sTM Effectiveness ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C. ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012 ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 ImmuPharma PLC Appoints Cenkos Securities as Joint Broker PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011 ImmuPharma PLC Appoints Head of Investor Relations ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger Interviews 2015: Lupuzor™ founder Professor Sylviane Muller Biotech Capital Conference: 6th February 2017 Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM) – April 2018 Dr Navid Malik, analyst at The Life Sciences Division talks to Directors Talk about the opportunities for Lupuzor™ – Sept 2019 ImmuPharma chair hails “successful” recruitment for Lupuzor™ trials ImmuPharma Chairman details £2.66m financing and open label extension study – July 2019 ImmuPharma chairman more optimistic on results for its Lupuzor drug – May 2018 ImmuPharma firmly committed to Lupuzor ahead of managed access programme – 18th Sept 2018 Immupharma Plc – A multi-billion dollar selling drug ImmuPharma PLC Chairman Tim McCarthy Progress, Opportunity, Milestones ImmuPharma PLC New Phase III Lupuzor Trial Data Positive – May 2018 Immupharma Plc On Track, Looking Good and Excited – 18th May 2017 ImmuPharma plc positive results and new initiation note – May 2019 Immupharma PLC still confident on Lupuzor’s future – 19th April 2018 ImmuPharma PLC to open Lupuzor™ trial site in Mauritius Immupharma raises £8.3mln for Lupuzor™ trials & early stage pipeline ImmuPharma’s McCarthy on phase III Lupuzor™ trials Interview with The Life Sciences Division’s executive director Dr Navid Malik – 5th June 2019 Interview with Tim McCarthy, Chairman of Immupharma – 19 Jan 2018 Investigators meeting, December 2015, Paris Lupuzor’s™ pivotal phase III trial Lupuzor™ could treat a number of diseases, says creator Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update Proactive Investors interview with Chairman Tim McCarthy – May 2019 Q&A with Vadim Alexandre Head of Research at Northland Capital Partners Share Talk interview – 3 October 2018 Successful AstraZeneca lupus study bodes well for ImmuPharma’s Lupuzor™ – Sept 2019 Tim McCarthy talks to Proactive Investor on 2 February 2018 Tim McCarthy talks to Proactive Investors – 6th February 2017 Tim McCarthy updates on Phase III study – 17th May 2017 Tim McCarthy, Chairman of ImmuPharma – 17th May 2017 Tim McCarthy, Chairman of ImmuPharma #IMM – 26th January 2017 Vox market audio interview with Immupharma Chairman Tim McCarthy – 19th April 2018 Vox Markets interview Tim McCarthy, Chairman of ImmuPharma (IMM) – July 2019 Vox Markets Podcast – 18th September Vox markets podcast – July 2019 Vox Markets podcast featuring an interview with Dr Navid Malik Executive Director at The Life Sciences Division – Sept 2019 Vox markets podcast with Tim McCarthy – May 2019
Cookies This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the Cookie Policy I Accept 